Oncternal Therapeutics logo
Oncternal Therapeutics
ONCT | NASDAQ
Chart Builder DCF Calculator
$0.53
-$0.16 (-23.63%)
At close: Dec 02, 2024, 04:00 PM ET

Oncternal Therapeutics Company Profile

Company profile explained

Company Profile

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfolio features zilovertamab, a humanized monoclonal antibody designed to bind to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule that works by inhibiting the biological activity of ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a chimeric antigen receptor T-cell (CAR-T) therapy candidate also targeting ROR1, as well as ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer and other cancers driven by androgen receptors. The company holds various license agreements with institutions such as the Regents of the University of California, Georgetown University, The University of Texas MD Anderson Cancer Center, Shanghai Pharmaceutical (USA) Inc., and the University of Tennessee Research Foundation. Furthermore, it engages in a research collaboration with Celularity Inc. to explore placental-derived cellular therapies that also target ROR1. Its headquarters are located in San Diego, California.

Key Executives

Name Position
James Breitmeyer President, Chief Executive Officer & Director
Richard G. Vincent Chief Financial Officer & Treasurer
Chase C. Leavitt General Counsel & Secretary
Pablo Urbaneja Senior Vice President of Corporate Development
Rajesh Krishnan Chief Technical & Scientific Officer

Latest SEC Filings

No SEC filings available
View All SEC Filings ➞
Oncternal Therapeutics
Oncternal Therapeutics logo
Country United States
IPO Date Feb 3, 2004
Industry Biotechnology
Sector Healthcare
Employees 27
CEO James B. Breitmeyer

Contact Details

12230 El Camino Real San Diego, California 92130 United States

Stock Details

Ticker Symbol ONCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001260990
CUSIP Number 68236P206
ISIN Number US68236P2065
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.